Scientists have reprogrammed brain immune cells using a newly identified molecule called OLE to combat Alzheimer’s disease, reducing toxic plaque in disease models.
The molecule restored microglia, the brain’s immune cells, to a protective state in Alzheimer’s disease models. This action reduced toxic amyloid plaque and improved memory, pointing to a potential new approach to treating the condition.
Microglia are specialized immune cells in the brain that play a role in clearing waste and maintaining a healthy environment. In Alzheimer’s disease, their function can become impaired, contributing to the accumulation of harmful substances and inflammation.
Amyloid plaques, formed by the buildup of amyloid-beta protein, are a hallmark of Alzheimer’s disease and are associated with the cognitive decline that characterizes the disorder. Reducing these plaques has been a major focus of research into potential treatments.
By restoring microglia to a protective state, the OLE molecule enabled a reduction in amyloid plaque and an improvement in memory within the models studied. Such findings offer insight into mechanisms that could be harnessed for therapy.
Research conducted in disease models represents an early stage in the development of potential treatments, requiring further study before any application to humans. Nonetheless, the identification of OLE and its effects on microglia adds to the search for effective Alzheimer’s therapies.
The work contributes to ongoing efforts to address Alzheimer’s disease, a major cause of dementia, by targeting the brain’s immune response as a means of reducing the disease’s harmful effects.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/